- Home
- ZUMZ vs ZBIO Comparison
ZUMZ vs ZBIO Comparison
Compare ZUMZ & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZUMZ
- ZBIO
- Stock Information
- Founded
- ZUMZ 1978
- ZBIO 2019
- Country
- ZUMZ United States
- ZBIO United States
- Employees
- ZUMZ 8700
- ZBIO N/A
- Industry
- ZUMZ Clothing/Shoe/Accessory Stores
- ZBIO
- Sector
- ZUMZ Consumer Discretionary
- ZBIO
- Exchange
- ZUMZ Nasdaq
- ZBIO NYSE
- Market Cap
- ZUMZ 274.4M
- ZBIO 268.7M
- IPO Year
- ZUMZ 2005
- ZBIO 2024
- Fundamental
- Price
- ZUMZ $14.32
- ZBIO $7.90
- Analyst Decision
- ZUMZ Hold
- ZBIO Strong Buy
- Analyst Count
- ZUMZ 2
- ZBIO 6
- Target Price
- ZUMZ $22.00
- ZBIO $31.83
- AVG Volume (30 Days)
- ZUMZ 318.9K
- ZBIO 130.1K
- Earning Date
- ZUMZ 03-13-2025
- ZBIO 03-25-2025
- Dividend Yield
- ZUMZ N/A
- ZBIO N/A
- EPS Growth
- ZUMZ N/A
- ZBIO N/A
- EPS
- ZUMZ N/A
- ZBIO N/A
- Revenue
- ZUMZ $889,202,000.00
- ZBIO $5,000,000.00
- Revenue This Year
- ZUMZ $3.43
- ZBIO N/A
- Revenue Next Year
- ZUMZ $1.97
- ZBIO N/A
- P/E Ratio
- ZUMZ N/A
- ZBIO N/A
- Revenue Growth
- ZUMZ 1.57
- ZBIO N/A
- 52 Week Low
- ZUMZ $12.67
- ZBIO $5.83
- 52 Week High
- ZUMZ $31.37
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- ZUMZ 48.38
- ZBIO N/A
- Support Level
- ZUMZ $12.67
- ZBIO N/A
- Resistance Level
- ZUMZ $14.68
- ZBIO N/A
- Average True Range (ATR)
- ZUMZ 0.78
- ZBIO 0.00
- MACD
- ZUMZ 0.16
- ZBIO 0.00
- Stochastic Oscillator
- ZUMZ 82.09
- ZBIO 0.00
About ZUMZ Zumiez Inc.
Zumiez Inc is a United-States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art from action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.